What is Beam Therapeutics's derivative liability, current?

Beam Therapeutics (BEAM) reported derivative liability, current of $5.2M in Q1 2026.

How has Beam Therapeutics's derivative liability, current changed year-over-year?

Beam Therapeutics's derivative liability, current decreased by 0.0% year-over-year, from $5.2M to $5.2M.

What is the long-term trend for Beam Therapeutics's derivative liability, current?

Over 5 years (2020 to 2025), Beam Therapeutics's derivative liability, current has grown at a -35.9% compound annual growth rate (CAGR), from $71.2M to $7.7M.

Beam Therapeutics BEAM Derivative Liability, Current

Derivative Liability, Current at other companies

BiogenBIIB

——

BioMarin PharmaceuticalsBMRN

——

Other financials

Income statement

See full

Revenue$31.7M+325%

Operating income-$107.2M+10.1%

Net income-$94.3M+12.9%

EPS (diluted)-$0.91+26.0%

Balance sheet

See full

Cash & equivalents$288.3M-45.4%

Total debt$250.8M+58.6%

Total equity$1.2B+3.1%

Total assets$1.5B+0.9%

Cash flow

See full

Operating cash flow-$128.5M-23.7%

CapEx$2.2M-27.2%

Free cash flow-$130.7M-22.2%

Valuation

See full

Market cap$3.42B+24.5%

Profitability

See full

Operating margin-226.6%-90.5pp

Net margin-742.7%—

FCF margin-234%-86.6pp

Returns & leverage

See full

Return on equity-47.1%—

Debt / equity0.2×+0.1×

Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesCurrent.

The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's derivative liability, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Beam Therapeutics's derivative liability, current?: Beam Therapeutics (BEAM) reported derivative liability, current of $5.2M in Q1 2026.
How has Beam Therapeutics's derivative liability, current changed year-over-year?: Beam Therapeutics's derivative liability, current decreased by 0.0% year-over-year, from $5.2M to $5.2M.
What is the long-term trend for Beam Therapeutics's derivative liability, current?: Over 5 years (2020 to 2025), Beam Therapeutics's derivative liability, current has grown at a -35.9% compound annual growth rate (CAGR), from $71.2M to $7.7M.